NVDA
NVIDIA
-- 138.380 TSLA
Tesla
-- 432.010 PLTR
Palantir
-- 80.400 RGTI
Rigetti Computing
-- 11.2408 AMD
Advanced Micro Devices
-- 125.180 
Key problem of $Novavax (NVAX.US)$ is lacking field data but...
We now know so called 90%+ effecacy rates in phase 3 tests for many vaccines are really ..., you know. They were conducted under special controls, for instance, exclude risky people, etc. Furthermore, mask mandate, etc. policies expanded their "effecacy" - actually accumulative effecacy - should be vaccine + mask, etc.
For $BioNTech (BNTX.US)$/ $Pfizer (PFE.US)$, $Moderna (MRNA.US)$, $AstraZeneca (AZN.US)$, $SINOPHARM (01099.HK)$, $Sinovac Biotech (SVA.US)$ (trade suspended), at least, we have lots of field data on safety and real effecacy. Unless you are corrupted health officials own lots of NVAX shares, how dare you introduce NVAX to replace known ones?
Not to mention, NVAX still has not given a plausible explanation of their low effecacy in phase 2b test conducted in South Africa. Rather, NVAX left (should we say "flee"?) S. Africa and conducted phase 3 in US and Mexico.
Not just in US and Europe, even in China, you can see several late comers, despite claim better than in-use HK:1099 and SVA (trade supspended), they got little business.
I doubt Chinese government want SVA resume trade in Nasdaq because the company now worth a lot. As I read, in volume, SAV has sold most vaccines, BNTX/PFE cam second, and 099 third.
By the way, 1099 does show good safety, much better than BNTX/PFE: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473339/
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
krithoonsuwan : This is the same situation as before Moderna was commercially used.
Dantan6 : Xiao char bo spreading speculation and rumors
YC Xiao : let's hear from scientists and doctors![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Raeann Loebs : I don't advocate to buy 1099 because it has many products thus revenue from vaccine sale could be diluted by others. This is somewhat like PFE. If you compare PFE vs BNTX, then you can find BNTX jumped far more than PFE.
wild horse : Perhaps 1099 should have created a separated company to make and sell vaccine but that didn't happen. It smanagement should go to Wall Street to learn more.
Ricchie Ng YC Xiao : Yup